Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective, single‐arm trial (LEAD trial)

Aims No pharmacological therapies are approved for non‐alcoholic fatty liver disease (NAFLD). Luseogliflozin, a sodium glucose cotransporter 2 inhibitor, has been developed for the treatment of adults with type 2 diabetes (T2DM). The aim of this prospective, single‐arm study is to evaluate the effic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology research 2019-01, Vol.49 (1), p.64-71
Hauptverfasser:	Sumida, Yoshio, Murotani, Kenta, Saito, Miyoko, Tamasawa, Atsuko, Osonoi, Yusuke, Yoneda, Masashi, Osonoi, Takeshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Alanine Alanine transaminase Clinical trials Collagen (type IV) Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Fatty liver Ferritin Fibrosis Hemoglobin Liver diseases luseogliflozin Magnetic resonance imaging Na+/glucose cotransporter non‐alcoholic fatty liver disease Patients Sodium Steatosis Transaminase type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!